Docoh
Loading...

BMRN Biomarin Pharmaceutical Inc. - Registered Shares

Employees

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

ESG term mentions

In last year of SEC filings
CleanEnvironmentEnvironmentalGreenGreenhouse Gas EmissionHazardLEEDMaterialsNatureOffsetPackagePackagingPandemicRaw MaterialsRecyclingRegenerativeRenewableSolarWasteWaterWindAccessAsianBenefitsBlackCalifornia Consumer Privacy ActCharityCommunityCustomerCyber SecurityCybersecurityData PrivacyData SecurityDeathDisabilityDiversityDrug PricingEmployeeEmployee Resource GroupEmployee RetentionEngagementEthnicEthnicityGenderGeneral Data Protection RegulationHealth CareHealthcareHireHiringHuman CapitalHuman ResourcesHuman RightsIncidentInjuriesLabor StandardsLGBTQMinorityPay EquityPerquisitesPrivacyProduct SafetyRacismRecallRecruitRecruitmentReimbursementRetentionRetirementSafetySatisfactionSkillSkillsSocialSocietyStakeholderSupplierSupply ChainTalentTrainingUnionVolunteerWomenWorkersWorkforceAnti-corruptionAssessmentAssuranceAuditBonusBriberyChronicClass Action LawsuitClassifiedClawbackCommitmentConflict of InterestControversyCorporate GovernanceCorporate PurposeCorporate Social ResponsibilityCorruptionDepartment ofDirector ResignationESGEthicsExecutive CompensationExpertFinedFraudGoalsGovernanceHedgingIncentiveIncentivizeIndependenceIndependentIndependent ChairInnovationInnovativeInvestigationLawsuitLead Independent DirectorLeadershipLitigationLong-termMajorityOverseeOversightPerquisitePlaintiffPledgingProcurementProxy AccessPurposeR&DReputationReputationalResearch and DevelopmentResponsibilityResponsibleSelf-evaluationStockholder EngagementStockholder OutreachStrategySustainabilitySustainableTargetsTaxTenureTransparencyTransparent

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
A total of 182,660,481 shares of common stock were entitled to vote as of March 29, 2021, the record date for the Annual Meeting. There were 159,678,491 shares of common stock present in person or represented by proxy at the Annual Meeting at which the stockholders were asked to vote on four proposals, each of which is described in more detail in the Proxy Statement, as supplemented by definitive additional materials filed with the SEC on May 17, 2021. Set forth below are the matters acted upon by the stockholders, and the final voting results of each such proposal.

Proposal No. 1: Election of Directors

Directors ElectedVote ForWithheldBroker
Non-Votes
Jean-Jacques Bienaimé139,640,53110,569,8099,468,151
Elizabeth McKee Anderson145,718,5084,491,8329,468,151
Willard Dere, M.D.146,207,9874,002,3539,468,151
Michael Grey71,714,68578,495,6559,468,151
Elaine J. Heron, Ph.D.136,447,24713,763,0939,468,151
Maykin Ho148,775,3241,435,0169,468,151
Robert J. Hombach147,291,6882,918,6529,468,151
V. Bryan Lawlis, Ph.D.144,017,0186,193,3229,468,151
Richard A. Meier145,888,5804,321,7609,468,151
David E.I. Pyott, M.D. (Hon.)145,602,3494,607,9919,468,151
Dennis J. Slamon, M.D., Ph.D.148,937,5591,272,7819,468,151


Based on the votes set forth above, BioMarin’s stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner, until the director’s death, resignation or removal. As described in